p.90 抽出テキスト

percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol 2019;4:747–55. https://doi.org/10.1001/jamacardio.2019. 1880 769. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J 2019;40:1553–62. https://doi.org/10. 1093/eurheartj/ehz059 770. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace 2020;22:33–46. https://doi.org/10.1093/europace/euz259 771. Haller PM, Sulzgruber P, Kaufmann C, Geelhoed B, Tamargo J, Wassmann S, et al. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019;5:226–36. https://doi.org/10.1093/ehjcvp/pvz021 772. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol 2020;5: 582–9. https://doi.org/10.1001/jamacardio.2019.6175 773. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An openlabel, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J 2018;200:17–23. https://doi.org/10.1016/ j.ahj.2018.03.001 774. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial. Circulation 2019;140:1921–32. https://doi.org/10.1161/CIRCULATIONAHA.119. 043308 775. Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, et al. Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous intervention. J Am Coll Cardiol 2022;79:417–27. https://doi. org/10.1016/j.jacc.2021.11.035 776. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/ benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation 2020;141:1618–27. https://doi.org/10.1161/CIRCULA TIONAHA.120.046534 777. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–691.e2. https://doi. org/10.1053/j.gastro.2019.05.056 778. Jeridi D, Pellat A, Ginestet C, Assaf A, Hallit R, Corre F, et al. The safety of long-term proton pump inhibitor use on cardiovascular health: a meta-analysis. J Clin Med 2022; 11:4096. https://doi.org/10.3390/jcm11144096 779. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3: 231–41. https://doi.org/10.1016/S2468-1253(18)30037-2 780. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619–29. https://doi.org/ 10.1016/j.jacc.2015.02.050 781. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation 2019;139:604–16. https:// doi.org/10.1161/CIRCULATIONAHA.118.036768 782. Jensen T, Thrane PG, Olesen KKW, Würtz M, Mortensen MB, Gyldenkerne C, et al. Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2023;9:208–19. https://doi.org/10.1093/ehjcvp/pvac058 783. Vitalis A, Shantsila A, Proietti M, Vohra RK, Kay M, Olshansky B, et al. Peripheral arterial disease in patients with atrial fibrillation: the AFFIRM study. Am J Med 2021;134:514–8. https://doi.org/10.1016/j.amjmed.2020.08.026 784. Wasmer K, Unrath M, Köbe J, Malyar NM, Freisinger E, Meyborg M, et al. Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease. Int J Cardiol 2015;199:223–8. https://doi.org/10.1016/j. ijcard.2015.06.094 785. Griffin WF, Salahuddin T, O’Neal WT, Soliman EZ. Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly. Europace 2016;18:794–8. https://doi.org/10.1093/europace/euv369 786. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nation wide database analysis. Atherosclerosis 2011;217:292–5. https://doi.org/10.1016/j. atherosclerosis.2011.03.033 787. Su MI, Cheng YC, Huang YC, Liu CW. The impact of atrial fibrillation on one-year mortality in patients with severe lower extremity arterial disease. J Clin Med 2022;11:1936. https://doi.org/10.3390/jcm11071936 788. Winkel TA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I, et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg 2010;40:9–16. https://doi.org/10.1016/j.ejvs.2010. 03.003 789. Nejim B, Mathlouthi A, Weaver L, Faateh M, Arhuidese I, Malas MB. Safety of carotid artery revascularization procedures in patients with atrial fibrillation. J Vasc Surg 2020; 72:2069–2078.e4. https://doi.org/10.1016/j.jvs.2020.01.074 790. Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014;35:242–9. https://doi.org/10.1093/eurheartj/eht492 791. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/10.1093/eurheartj/ ehx095 792. Schirmer CM, Bulsara KR, Al-Mufti F, Haranhalli N, Thibault L, Hetts SW. Antiplatelets and antithrombotics in neurointerventional procedures: guideline update. J Neurointerv Surg 2023;15:1155–62. https://doi.org/10.1136/jnis-2022-019844 793. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021;6:I–LXII. https://doi.org/10.1177/239698732198 9865 794. Caso V, Masuhr F. A narrative review of nonvitamin K antagonist oral anticoagulant use in secondary stroke prevention. J Stroke Cerebrovasc Dis 2019;28:2363–75. https://doi. org/10.1016/j.jstrokecerebrovasdis.2019.05.017 795. Fischer U, Koga M, Strbian D, Branca M, Abend S, Trelle S, et al. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med 2023;388:2411–21. https:// doi.org/10.1056/NEJMoa2303048 796. Oldgren J, Åsberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study. Circulation 2022;146:1056–66. https://doi.org/10.1161/CIRCULATIONAHA.122. 060666 797. Schreuder F, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, Kerkhoff H, Zock E, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in The Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol 2021;20:907–16. https://doi.org/ 10.1016/S1474-4422(21)00298-2 798. SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessormasked, pilot-phase, non-inferiority trial. Lancet Neurol 2021;20:842–53. https://doi. org/10.1016/S1474-4422(21)00264-7 799. Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, et al. Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. Am J Respir Crit Care Med 2017;195:205–11. https://doi.org/10.1164/rccm.201603-0618OC 800. Gundlund A, Olesen JB, Butt JH, Christensen MA, Gislason GH, Torp-Pedersen C, et al. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study. Eur Heart J 2020;41:1112–9. https://doi.org/10.1093/eurheartj/ ehz873 801. Induruwa I, Hennebry E, Hennebry J, Thakur M, Warburton EA, Khadjooi K. Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation? Eur J Intern Med 2022;98:32–6. https://doi.org/10.1016/j. ejim.2021.10.022 802. Ko D, Saleeba C, Sadiq H, Crawford S, Paul T, Shi Q, et al. Secondary precipitants of atrial fibrillation and anticoagulation therapy. J Am Heart Assoc 2021;10:e021746. https://doi.org/10.1161/JAHA.121.021746 803. Li YG, Borgi M, Lip GY. Atrial fibrillation occurring initially during acute medical illness: the heterogeneous nature of disease, outcomes and management strategies. Eur Heart J Acute Cardiovasc Care 2018;10:2048872618801763. https://doi.org/10.1177/ 2048872618801763 804. Lowres N, Hillis GS, Gladman MA, Kol M, Rogers J, Chow V, et al. Self-monitoring for recurrence of secondary atrial fibrillation following non-cardiac surgery or acute

ESC Guidelines                                                                                                                                                                                          3403

Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026